臨床検査59巻2号

2015年02月発行

今月の特集1 動脈硬化症の最先端

動脈硬化症の治療標的─脂質代謝を中心に

著者： 小倉正恒¹ 斯波真理子¹

所属機関： ¹国立循環器病研究センター研究所　病態代謝部

ページ範囲：P.133 - P.141

●創薬ターゲットとなる分子の発見は，単一遺伝子疾患患者の病態がヒントとなることが多い．

●ミクロソーム中性脂肪転送蛋白質（MTP），アポリポ蛋白B，PCSK9，コレステロールエステル転送蛋白質（CETP）に対する新しい阻害薬が第3相試験レベルまで開発が進んでいる．

●動脈硬化症の治療や予防の予測に役立つと期待される新しい検査法として患者高比重リポ蛋白質（HDL）のコレステロール引き抜き能の測定が挙げられる．

参考文献

1）Brown MS, Goldstein JL：Expression of the familial hypercholesterolemia gene in heterozygotes：mechanism for a dominant disorder in man. Science　185：61-63，1974

2）Samaha FF, McKenney J, Bloedon LT, et al：Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med　5：497-505，2008

3）Cuchel M, Bloedon LT, Szapary PO, et al：Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med　356：148-156，2007

4）Cuchel M, Meagher EA, du Toit Theron H, et al：Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet　381：40-46，2013

5）Raal FJ, Santos RD, Blom DJ, et al：Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet　375：998-1006，2010

6）Akdim F, Visser ME, Tribble DL, et al：Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol　105：1413-1419，2010

7）Stein EA, Dufour R, Gagne C, et al：Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation　126：2283-2292，2012

8）Akdim F, Stroes ES, Sijbrands EJ, et al：Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol　55：1611-1618，2010

9）Thomas GS, Cromwell WC, Ali S, et al：Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol　62：2178-2184，2013

10）Visser ME, Wagener G, Baker BF, et al：Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J　33：1142-1149，2012

11）Abifadel M, Varret M, Rabès JP, et al：Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet　34：154-156，2003

12）Cohen J, Pertsemlidis A, Kotowski IK, et al：Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet　37：161-165，2005

13）Cohen JC, Boerwinkle E, Mosley TH Jr, et al：Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med　354：1264-1272，2006

14）Koren MJ, Scott R, Kim JB, et al：Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL)：a randomised, double-blind, placebo-controlled, phase 2 study. Lancet　380：1995-2006，2012

15）Giugliano RP, Desai NR, Kohli P, et al：Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet　380：2007-2017，2012

16）Sullivan D, Olsson AG, Scott R, et al：Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients：the GAUSS randomized trial. JAMA　308：2497-2506，2012

17）Raal F, Scott R, Somaratne R, et al：Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia：the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation　126：2408-2417，2012

18）Colhoun HM, Robinson JG, Farnier M, et al：Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord　14：121，2014

19）Yamamoto T, Harada-Shiba M, Nakatani M, et al：Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids　1：e22，2012

20）Barter PJ, Caulfield M, Eriksson M, et al：Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med　357：2109-2122，2007

21）Schwartz GG, Olsson AG, Abt M, et al：Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med　367：2089-2099，2012

22）Gotto AM Jr, Cannon CP, Li XS, et al：Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol　113：76-83，2014

23）Bell TA 3rd, Graham MJ, Lee RG, et al：Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice. J Lipid Res　54：2647-2657，2013

24）Keene D, Price C, Shun-Shin MJ, et al：Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ　349：g4379，2014

25）Khera AV, Cuchel M, de la Llera-Moya M, et al：Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med　364：127-135，2011